Severe Gastric Side Effects Include Stomach Paralysis, Gastroparesis, And Intestinal Blockages
Ozempic has been approved by the FDA as a treatment for diabetes which is increasingly used "off-label" for weight loss purposes. Wegovy is a higher-dose version of Ozempic that is FDA-approved to treat obesity. Both of these relatively new drugs, from the pharmaceutical company Novo Nordisk, contain the active ingredient semaglutide. In the several years since being on the market, there have been an increasing number of so-called "semaglutide-related" gastroparesis, stomach paralysis, and intestinal blockage cases diagnosed in patients using Ozempic or Wegovy.
Related to this situation, due to a "Potential Signal of a Serious Risk / New Safety Information" about intestinal obstruction in patients using Ozempic and Wegovy -- as well as other drugs in the Glucagon-like peptide 1 (GLP-1) receptor agonists class of drugs -- the FDA is evaluating the need for regulatory action. See "April - June 2022 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)".
We point out that the current drug labels for Ozempic and Wegovy do not warn about gastroparesis, stomach paralysis, and intestinal blockages or obstructions being potential side effects of Ozempic and Wegovy. As a result, patients are likely unaware that they are at risk for developing one of these severe gastric side effects, which can require hospitalization and surgery to treat. Furthermore, gastroparesis is a long-term, chronic condition that can be irreversible even after a patient stops using Ozempic or Wegovy. Gastroparesis may also be called delayed gastric emptying.
Strictly Confidential, No Obligation.
This failure to warn doctors about these potential serious stomach or intestinal side effects associated with Ozempic and Wegovy has resulted in drug injury lawsuits filed against Novo Nordisk on behalf of patients who have been diagnosed with gastroparesis, stomach paralysis, and intestinal blockages.
Of course, we will continue to monitor the medical, regulatory, and legal sectors for more information concerning these severe gastric side effects of Ozempic and Wegovy. And be assured we will report significant developments going forward here on Drug Injury Watch.
If we can be of assistance with a possible drug injury lawsuit involving "semaglutide-related" gastroparesis, stomach paralysis, intestinal blockage, or intestinal blockage diagnosed in a patient using Ozempic or Wegovy, please do not hesitate to contact us.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (Website content is written by Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Attorney Tom Lamb does all case reviews)